TY - JOUR
T1 - COVID-19 in Pregnant Women With Rheumatic Disease
T2 - Data From the COVID-19 Global Rheumatology Alliance
AU - Bermas, Bonnie L.
AU - Gianfrancesco, Milena
AU - Tanner, Helen L.
AU - Seet, Andrea M.
AU - Aguiar, Mathia C.
AU - Al Adhoubi, Nasra K.
AU - Al Emadi, Samar
AU - Cunha, Bernardo M.
AU - Flood, Rachael
AU - Kusevich, Daria A.
AU - McCarthy, Eoghan M.
AU - Patel, Naomi J.
AU - Ruderman, Eric M.
AU - Sattui, Sebastian E.
AU - Sciascia, Savino
AU - Siddique, Faizah
AU - Valenzuela-Almada, Maria O.
AU - Wise, Leanna M.
AU - Worthing, Angus B.
AU - Zell, Jo Ann
AU - Bhana, Suleman
AU - Costello, Wendy
AU - Duarte-Garcia, Ali
AU - Grainger, Rebecca
AU - Gossec, Laure
AU - Hausmann, Jonathan S.
AU - Hyrich, Kimme
AU - Lawson-Tovey, Saskia
AU - Liew, Jean W.
AU - Sirotich, Emily
AU - Sparks, Jeffrey A.
AU - Sufka, Paul
AU - Wallace, Zachary S.
AU - Machado, Pedro M.
AU - Strangfeld, Anja
AU - Clowse, Megan E.B.
AU - Yazdany, Jinoos
AU - Robinson, Philip C.
N1 - Funding Information:
Research Consortium and Vasculitis Foundation outside the submitted work. LMW declares consulting for Aurinia outside the submitted work. SB declares nonbranded consulting for AbbVie, Horizon, Pfizer, and Novartis. ADG declares grants from the Centers for Disease Control and Prevention, the Rheumatology Research Foundation Scientist Development Award, the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, the Women’s Health Career Enhancement Award, and the Eaton Family Career Development Award. RG declares AbbVie, Cornerstones, Janssen, and Pfizer, all outside the submitted work. LG declares research grants from Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB, all outside the submitted work. JSH declares grants from the Rheumatology Research Foundation and salary support from the Childhood Arthritis and Rheumatology Research Alliance (CARRA); and consulting for Novartis, Biogen, and Pfizer (< $10,000), all unrelated to this work. KH declares honoraria from AbbVie, and grants from BMS, Pfizer, and UCB. JWL declares research funding from Pfizer unrelated to this work. JAS declares research support from Amgen and BMS, and performed consultancy for BMS, Gilead, Inova, Janssen, and Optum, unrelated to this work. ZSW declares grant support from BMS and Principia, and has received consulting fees from MedPace and Viela Bio for unrelated work. PMM declares consulting/speaker’s fees from AbbVie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche, and UCB, all unrelated to this manuscript, and is supported by the NIHR, University College London Hospitals, Biomedical Research Centre. AS declares lecture honoraria from AbbVie, BMS, Celltrion, MSD, Pfizer, Roche, and UCB, outside the submitted work. MEBC declares consulting for GSK, AstraZeneca, and UCB; and grants from GSK and Pfizer, outside the submitted work. JY declares personal fees from AstraZeneca, personal fees from Eli Lilly, and grants from Pfizer and Gilead, outside the submitted work. PCR declares personal feesAbbVie, Atom Bioscience, Gilead, Eli Lilly, Novartis, Roche, UCB, BMS, Janssen, and Pfizer, all outside the submitted work. The remaining authors declare no competing interests relevant to this article. Address correspondence to Assoc. Prof. P.C. Robinson, University of Queensland School of Clinical Medicine, Royal Brisbane & Women’s Hospital, Herston, Queensland 4006, Australia. Email: philip.robinson@uq.edu.au. Accepted for publication August 11, 2021.
Funding Information:
21W. Costello, Irish Children’s arthritis network (iCan), Tipperary, Ireland; 22R. Grainger, MBChB, PhD, FRACP, Department of Medicine, University of Otago, Wellington, New Zealand; 23L. Gossec, MD, PhD, Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, and Pitié-Salpêtrière Hospital, AP-HP, Sorbonne Université, Rheumatology Department, Paris, France; 24J.S. Hausmann, MD, Program in Rheumatology, Division of Immunology, Boston Children’s Hospital, and Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; 25K. Hyrich, MD, PhD, FRCPC, Centre for Epidemiology Versus Arthritis, The University of Manchester, and National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK; 26S. Lawson-Tovey, BA, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, and Centre for Genetics and Genomics Versus Arthritis, The University of Manchester, Manchester, UK; 27J.W. Liew, MS, MD, Boston University School of Medicine, Boston, Massachusetts, USA; 28E. Sirotich, BSc, Department of Health Research, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; 29J.A. Sparks, MD, MMSc, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA; 30P. Sufka, MD, Healthpartners, St. Paul, Minnesota, USA; 31Z.S. Wallace, MD, MSc, Rheumatology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; 32P.M. Machado, MD, PhD, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, and National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, UK; 33A. Strangfeld, MD, Epidemiology Unit, German Rheumatism Research Centre (DRFZ) Berlin, Berlin, Germany; 34M.E.B. Clowse, MD, MPH, Duke University School of Medicine, Durham, North Carolina, USA; 35P.C. Robinson, MBChB, PhD, FRACP, Associate Professor, University of Queensland School of Clinical Medicine, Faculty of Medicine, Queensland, Australia, and Royal Brisbane & Women’s Hospital, Metro North Hospital & Health Service, Herston, Queensland, Australia. EMR declares consulting for AbbVie, Amgen, BMS, Horizon, Janssen, Lilly, Novartis, and Pfizer; and research grants from Corrona and Pfizer, all unrelated to this work. SES declares funding from the Vasculitis Clinical
Publisher Copyright:
© 2022 The Journal of Rheumatology.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Objective. To describe coronavirus disease 2019 (COVID-19) and pregnancy outcomes in patients with rheumatic disease who were pregnant at the time of infection. Methods. Since March 2020, the COVID-19 Global Rheumatology Alliance has collected cases of patients with rheumatic disease with COVID-19. We report details of pregnant women at the time of COVID-19 infection, including obstetric details separately ascertained from providers. Results. We report on 39 patients, including 22 with obstetric detail available. The mean and median age was 33 years, range 24–45 years. Rheumatic disease diagnoses included rheumatoid arthritis (n = 9), systemic lupus erythematosus (n = 9), psoriatic arthritis/other inflammatory arthritides (n = 8), and antiphospholipid syndrome (n = 6). Most had a term birth (16/22), with 3 preterm births, 1 termination, and 1 miscarriage; 1 woman had yet to deliver at the time of report. One-quarter (n = 10/39) of pregnant women were hospitalized following COVID-19 diagnosis. Two of 39 (5%) required supplemental oxygen (both hospitalized); no patients died. The majority did not receive specific medication treatment for their COVID-19 (n = 32/39, 82%), and 7 patients received some combination of antimalarials, colchicine, anti–interleukin 1β, azithromycin, glucocorticoids, and lopinavir/ritonavir. Conclusion. Women with rheumatic diseases who were pregnant at the time of COVID-19 had favorable outcomes. These data have limitations due to the small size and methodology; however, they provide cautious optimism for pregnancy outcomes for women with rheumatic disease particularly in comparison to the increased risk of poor outcomes that have been reported in other series of pregnant women with COVID-19.
AB - Objective. To describe coronavirus disease 2019 (COVID-19) and pregnancy outcomes in patients with rheumatic disease who were pregnant at the time of infection. Methods. Since March 2020, the COVID-19 Global Rheumatology Alliance has collected cases of patients with rheumatic disease with COVID-19. We report details of pregnant women at the time of COVID-19 infection, including obstetric details separately ascertained from providers. Results. We report on 39 patients, including 22 with obstetric detail available. The mean and median age was 33 years, range 24–45 years. Rheumatic disease diagnoses included rheumatoid arthritis (n = 9), systemic lupus erythematosus (n = 9), psoriatic arthritis/other inflammatory arthritides (n = 8), and antiphospholipid syndrome (n = 6). Most had a term birth (16/22), with 3 preterm births, 1 termination, and 1 miscarriage; 1 woman had yet to deliver at the time of report. One-quarter (n = 10/39) of pregnant women were hospitalized following COVID-19 diagnosis. Two of 39 (5%) required supplemental oxygen (both hospitalized); no patients died. The majority did not receive specific medication treatment for their COVID-19 (n = 32/39, 82%), and 7 patients received some combination of antimalarials, colchicine, anti–interleukin 1β, azithromycin, glucocorticoids, and lopinavir/ritonavir. Conclusion. Women with rheumatic diseases who were pregnant at the time of COVID-19 had favorable outcomes. These data have limitations due to the small size and methodology; however, they provide cautious optimism for pregnancy outcomes for women with rheumatic disease particularly in comparison to the increased risk of poor outcomes that have been reported in other series of pregnant women with COVID-19.
KW - COVID-19
KW - anti-TNF
KW - disease-modifying antirheumatic drug
KW - rheumatoid arthritis
KW - rheumatology
UR - http://www.scopus.com/inward/record.url?scp=85123225600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123225600&partnerID=8YFLogxK
U2 - 10.3899/jrheum.210480
DO - 10.3899/jrheum.210480
M3 - Article
C2 - 34470798
AN - SCOPUS:85123225600
SN - 0315-162X
VL - 49
SP - 110
EP - 114
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 1
ER -